Aurinia Pharmaceuticals Inc. Increase Decrease In Operating Lease Liability
Aurinia Pharmaceuticals Inc. (AUPH) reported Increase Decrease In Operating Lease Liability of -$441.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$227.00K.
- Aurinia Pharmaceuticals Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$214.00K.
- Aurinia Pharmaceuticals Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$202.00K.
- Aurinia Pharmaceuticals Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$205.00K.
- Aurinia Pharmaceuticals Inc. increase decrease in operating lease liability for fiscal 2025 was -$802.00K.
- Aurinia Pharmaceuticals Inc. increase decrease in operating lease liability for fiscal 2024 was -$750.00K.
- Aurinia Pharmaceuticals Inc. increase decrease in operating lease liability for fiscal 2023 was -$673.00K.
- Aurinia Pharmaceuticals Inc. increase decrease in operating lease liability for fiscal 2022 was -$652.00K, a 296.39% decline from fiscal 2021.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$227.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$441.00K 10-Q · filed 2026-08-06 | -$643.00K derived: sum of 3 quarters · filed 2026-08-06 | -$848.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$214.00K 10-Q · filed 2026-05-07 | -$416.00K derived: sum of 2 quarters · filed 2026-05-07 | -$621.00K derived: sum of 3 quarters · filed 2026-05-07 | -$821.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$202.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$407.00K derived: sum of 2 quarters · filed 2026-02-26 | -$607.00K derived: sum of 3 quarters · filed 2026-08-06 | -$802.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | -$205.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$405.00K derived: sum of 2 quarters · filed 2026-08-06 | -$600.00K 10-Q · filed 2025-11-04 | -$800.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$395.00K 10-Q · filed 2026-08-06 | -$595.00K derived: sum of 3 quarters · filed 2026-08-06 | -$780.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$195.00K 10-Q · filed 2026-05-07 | -$395.00K derived: sum of 2 quarters · filed 2026-05-07 | -$580.00K derived: sum of 3 quarters · filed 2026-05-07 | -$764.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$385.00K derived: sum of 2 quarters · filed 2026-02-26 | -$569.00K derived: sum of 3 quarters · filed 2026-02-26 | -$750.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | -$185.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$369.00K derived: sum of 2 quarters · filed 2025-11-04 | -$550.00K 10-Q · filed 2025-11-04 | -$724.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$184.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$365.00K 10-Q · filed 2025-07-31 | -$539.00K derived: sum of 3 quarters · filed 2026-02-26 | -$719.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$181.00K 10-Q · filed 2025-05-12 | -$355.00K derived: sum of 2 quarters · filed 2026-02-26 | -$535.00K derived: sum of 3 quarters · filed 2026-02-26 | -$698.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$174.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$354.00K derived: sum of 2 quarters · filed 2026-02-26 | -$517.00K derived: sum of 3 quarters · filed 2026-02-26 | -$673.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | -$180.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$343.00K derived: sum of 2 quarters · filed 2024-11-07 | -$499.00K 10-Q · filed 2024-11-07 | -$600.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$163.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$319.00K 10-Q · filed 2024-08-01 | -$420.00K derived: sum of 3 quarters · filed 2025-02-27 | -$616.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$156.00K 10-Q · filed 2024-05-02 | -$257.00K derived: sum of 2 quarters · filed 2025-02-27 | -$453.00K derived: sum of 3 quarters · filed 2025-02-27 | -$640.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$101.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$297.00K derived: sum of 2 quarters · filed 2025-02-27 | -$484.00K derived: sum of 3 quarters · filed 2025-02-27 | -$652.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | -$196.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$383.00K derived: sum of 2 quarters · filed 2023-11-02 | -$551.00K 10-Q · filed 2023-11-02 | -$718.00K derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | -$187.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$355.00K 10-Q · filed 2023-08-03 | -$522.00K derived: sum of 3 quarters · filed 2024-02-15 | -$552.00K derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$168.00K 10-Q · filed 2023-05-04 | -$335.00K derived: sum of 2 quarters · filed 2024-02-15 | -$365.00K derived: sum of 3 quarters · filed 2024-02-15 | -$310.00K derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$167.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$197.00K derived: sum of 2 quarters · filed 2024-02-15 | -$142.00K derived: sum of 3 quarters · filed 2024-02-15 | $332.00K 10-K · filed 2024-02-15 |
| 2021-09-30 | -$30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $25.00K derived: sum of 2 quarters · filed 2022-11-03 | $499.00K 10-Q · filed 2022-11-03 | $608.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $55.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $529.00K 10-Q · filed 2022-08-04 | $638.00K derived: sum of 3 quarters · filed 2023-02-28 | $2.73M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $474.00K 10-Q · filed 2022-05-10 | $583.00K derived: sum of 2 quarters · filed 2023-02-28 | $2.68M derived: sum of 3 quarters · filed 2023-02-28 | |
| 2020-12-31 | $109.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.21M derived: sum of 2 quarters · filed 2023-02-28 | $8.41M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $8.30M 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | $6.20M 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |